Weill Cornell Myeloma Center

05/09/2025

Our team member Dr. Mateo Mejia is dedicated to caring for patients with . Learn more about his background, , and dedication to giving back via Medscape:

Hematologist-oncologist Mateo Mejia Saldarriaga, MD, combines clinical care with research aimed at helping patients with treatment-resistant multiple myeloma.

02/19/2025

At the Lymphoma, Leukemia & Myeloma Congress , Dr. Mateo Mejia spoke with Oncology Learning Network about the latest clinical trial data on using CAR T-cell therapies for relapsed/refractory :

Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.

02/07/2025

El Dr. Mateo Mejia habló con The Leukemia & Lymphoma Society en su podcast en español sobre que es el mieloma múltiple, como se presenta, y cuáles son los últimos avances en su tratamiento:

En este episodio conocemos al Dr. Mateo Mejia Saldarriaga de Weill Cornell Medicine, hospital NewYork-Presbyterian. Únase para aprender cómo los avances científicos han transformado el tratamiento de mieloma dándole lugar a mejores resultados y pronósticos para pacientes. DESCARGAR TRANSCRIPCI....

10/08/2024

El Dr. Mateo Mejia estará presentando en el evento de The Leukemia & Lymphoma Society sobre la importancia de la comunicación entre el paciente y su equipo médico en el tratamiento para cáncer hematológico. Si estas interesando en conocer más información sobre como navegar el diagnostico de cáncer y algunos de los recursos para la comunidad Latina regístrate en el link: https://msg.lls.org/Oct19

Dr. Mateo Mejia is speaking at a The Leukemia & Lymphoma Society program in Spanish on the importance of communication between patients and their blood cancer care team. Learn about navigating a diagnosis and resources available for the Latino community. Register here: https://msg.lls.org/Oct19

08/08/2024

New led by Drs. Mateo Mejia, Ruben Niesvizky and Mark Bustoros showed that a simple blood test may help predict whether patients with relapsed will respond to chimeric antigen (CAR) T-cell therapy:

A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to CAR T-cell immunotherapy, according to a recent report.

06/25/2024

Join Dr. Cara Rosenbaum and other experts for a free in-person meeting on 6/29 in NYC. Learn more and register: https://bit.ly/3xHkRBY

03/18/2024

This , we’re bringing you up to speed on the differences between & other plasma cell disorders. Monoclonal gammopathy of undetermined significance or is a blood disorder where less than 10% of plasma cells are abnormal: https://bit.ly/3pcem5Z

03/15/2024

Join Dr. Mateo Mejia and oncology social worker Chelsea Cerillo at The Leukemia & Lymphoma Society event on 3/26. Register to learn about how this impacts the black community, available treatments & resources for coping with a diagnosis https://bit.ly/3vixJxc

03/13/2024

Prior to a multiple myeloma diagnosis, many patients will have a precursor condition that causes changes in their bone marrow, but doesn’t cause the traditional symptoms or organ damage associated with myeloma.These precursor conditions, known as either monoclonal gammopathy of undetermined signif...

03/08/2024

Bispecific T-Cell engager (BiTE) therapy is a novel approach that can help the body’s immune system target and kill cells. https://bit.ly/3uS4UYi

03/06/2024

March is . is a that impacts the plasma cells and the body’s ability to fight infections. https://bit.ly/49wtv48